Core Insights - Lexaria Bioscience Corp. has released additional data from its Phase 1b clinical study GLP-1-H24-4, which focuses on the efficacy of its DehydraTECH™ technology compared to Rybelsus® [1][2] Secondary Efficacy Parameters - At week 16, the DHT arms showed no statistically significant differences compared to the Rybelsus® control in mean fasting glucose, cholesterol, and LDL cholesterol [3] Body Composition - The DHT-semaglutide arm showed a modest reduction in fat mass of -1.08 kg and total mass of -1.40 kg, while the Rybelsus® control arm achieved greater reductions of -3.55 kg in fat mass and -5.36 kg in total mass, with a higher reduction in lean mass of -1.72 kg [4] Blood Pressure Analyses - The DHT-CBD arm achieved significant reductions in blood pressure, with a mean change of -4.6 mmHg in systolic and -4.0 mmHg in diastolic blood pressure at week 4 [5][6] Pharmacokinetic Exploratory Analyses - Plasma CBD concentrations were quantifiable through week 16 in the DHT-CBD arms, while semaglutide concentrations were not quantifiable due to assay issues, although preliminary tests indicated measurable levels [8] Health Survey Results - Participants in the DHT-semaglutide arm reported mean improvements of over 5 points in physical components and over 3 points in mental components of the SF-36 health survey, compared to modest improvements in the Rybelsus® control arm [9][10] Overall Conclusions and Next Steps - The study met its primary endpoint, demonstrating good safety and tolerability of all DHT test articles, with positive findings across various parameters compared to Rybelsus® [11] Future Plans - Lexaria plans to pursue further clinical testing with a DHT + SNAC + semaglutide composition and is in discussions with a pharmaceutical company regarding the dataset from the study [15][17][18]

 Kelowna, British Columbia – December 16, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,661,600 shares of its common stock, par value $0.001 per share, at a purchase price of $1.315 per share. In addition, in a concurrent private placement, the Company issued unregiste ...

Core Viewpoint - Lexaria Bioscience Corp. has announced a definitive agreement for a registered direct offering of 2,661,600 shares of common stock at a price of $1.315 per share, along with a concurrent private placement of unregistered warrants to purchase the same number of shares at an exercise price of $1.19 per share [1][2]. Group 1: Offering Details - The total gross proceeds from the offering are expected to be approximately $3.5 million before deducting fees and expenses [2]. - The offering is being conducted under a "shelf" registration statement that was declared effective by the SEC on January 30, 2025 [3]. - The warrants will be immediately exercisable and will expire five years from the effectiveness of the resale registration statement [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to advance research and development efforts, fund working capital, and cover other general corporate purposes [2]. Group 3: Company Background - Lexaria Bioscience Corp. specializes in drug delivery platforms, particularly its patented DehydraTECH™ technology, which enhances the absorption of drugs through oral delivery [6][7]. - The company holds a robust intellectual property portfolio with 56 patents granted and additional patents pending worldwide [7].

Core Insights - Lexaria Bioscience Corp. has extended its Material Transfer Agreement (MTA) with PharmaCO until April 30, 2026, to allow for the review of data from an Australian study [2][3] - The MTA enables continued collaboration and strategic planning discussions between Lexaria and PharmaCO's clinical development team [2] - Lexaria's DehydraTECH™ technology aims to enhance drug delivery through oral administration, improving bio-absorption and reducing side effects [4] Summary by Sections Material Transfer Agreement Update - The MTA originally signed on September 4, 2024, has been extended to accommodate PharmaCO's review of Lexaria's Australian study data [2] - This extension allows both parties to maintain their relationship and keep the temporary exclusive license active [2] Pre-Clinical Studies and Future Expectations - Initial pre-clinical studies examining pharmacokinetics in animals have been completed [3] - Lexaria is awaiting PharmaCO's review of safety, pharmacokinetic, and efficacy data from its independent Australian human clinical study, with final results expected by the end of Q4 2025 [3] About Lexaria and DehydraTECH - DehydraTECH™ is a patented drug delivery platform that enhances the absorption of various drugs through oral delivery [4] - Lexaria holds a strong intellectual property portfolio with 54 patents granted and additional patents pending globally [4]

Core Points - Lexaria Bioscience Corp. has closed a registered direct offering of 2,666,667 shares at a price of $1.50 per share, raising approximately $4.0 million before expenses [1][3] - The company also issued unregistered warrants for the purchase of an equal number of shares at an exercise price of $1.37, which are immediately exercisable and expire in five years [1][2] - The financing aims to enhance Lexaria's options for its 2026 R&D and business development plans, focusing on executing research initiatives that drive intellectual property and shareholder value [2] Financial Details - The gross proceeds from the offering were approximately $4.0 million, which will be used for working capital and general corporate purposes [3] - The shares were offered under a "shelf" registration statement effective since January 30, 2025, and the offering was conducted in compliance with SEC regulations [4] Warrants and Securities - The warrants were issued in a private placement and are not registered under the Securities Act, limiting their sale in the U.S. without an effective registration statement [5] - The company emphasizes that the offering does not constitute an offer to sell or solicit any offers to buy the securities in jurisdictions where such actions would be unlawful [6] Technology and Intellectual Property - Lexaria's DehydraTECH™ platform enhances drug delivery through oral administration, improving bio-absorption and reducing side effects [7] - The company holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide [7]

Core Points - Lexaria Bioscience Corp. has entered into a definitive agreement to sell 2,666,667 shares of common stock at a price of $1.50 per share in a registered direct offering [1] - Concurrently, the company will issue unregistered warrants to purchase an additional 2,666,667 shares at an exercise price of $1.37 per share, which will be immediately exercisable and expire in five years [1] - The total gross proceeds from the offering are expected to be approximately $4.0 million before deducting fees and expenses [2] Offering Details - The shares are being offered under a "shelf" registration statement that was declared effective by the SEC on January 30, 2025 [3] - The offering is made only by means of a prospectus, which will be filed with the SEC and available on their website [3] - The warrants are issued in a private placement and have not been registered under the Securities Act, limiting their sale in the U.S. [4] Company Overview - Lexaria's DehydraTECH™ technology enhances drug delivery through oral administration, improving bio-absorption and reducing side effects [6] - The company holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide [6]

Core Insights - The study conducted by Lexaria Bioscience Corp. indicates that the DehydraTECH processing of semaglutide enhances its brain biodistribution compared to conventional formulations, potentially improving safety and efficacy [1][3][6] Study Findings - The primary objective of the study was to assess whether DehydraTECH processing significantly improves the biodistribution of semaglutide [2] - The DehydraTECH-FTS composition showed a higher apparent trend in brain biodistribution across all tested doses, with the 5mg DehydraTECH-FTS achieving greater brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent [3][5] - Fluorescent imaging revealed that all three DehydraTECH doses tested had higher fluorescence in key brain regions compared to naïve and vehicle groups, while only the highest dosage of Rybelsus® surpassed these groups [5] Mechanism and Implications - The study suggests that enhanced brain biodistribution may be linked to the pharmacodynamic performance of GLP-1 drugs, which are known to interact with brain neurochemistry [6][7] - Semaglutide's ability to regulate body weight through GLP-1 receptor activation in the brain could lead to appetite suppression without common side effects like nausea [6] - Lexaria's findings may support the development of safer and more effective GLP-1 drugs in the future [8] Research Methodology - The preclinical pilot study involved Sprague Dawley rats and utilized non-invasive whole-body imaging and ex vivo organ analysis to evaluate the biodistribution of oral semaglutide [9][12] - A total of 25 male rats were used, with 22 allocated for dosing and 3 as untreated controls, examining both DehydraTECH and Rybelsus® equivalent compositions [12][13] Technology Overview - DehydraTECH is a patented drug delivery platform that enhances the absorption and effectiveness of various drugs, including those that cross the blood-brain barrier [14]

Core Viewpoint - Lexaria Bioscience Corp. will participate in the 27th Annual H.C. Wainwright Global Investment Conference from September 8th to September 10th, 2025, highlighting its innovative drug delivery technology, DehydraTECH [1][3]. Company Overview - Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on improving the way drugs enter the bloodstream through oral delivery [1][3]. - The company operates a licensed in-house research laboratory and holds a strong intellectual property portfolio with 50 patents granted and additional patents pending worldwide [3]. Technology Highlights - DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform that enhances bio-absorption, reduces side effects, and improves drug delivery across the blood-brain barrier [3].

Core Insights - Lexaria Bioscience Corp. has received 2 new international patents, increasing its total patent portfolio to 50 [1][2] - The new patents include one for treating epilepsy and another for sublingual delivery of nicotine, enhancing Lexaria's intellectual property protection [2][3] - The epilepsy drug market was valued at US$9.5 billion in 2023 and is projected to exceed US$15 billion by 2032, indicating significant growth potential [4] - The global retail oral nicotine market was valued at US$5.5 billion in 2023 and is expected to grow at a rate of 26% per year until at least 2030 [5] Company Developments - Lexaria's new patent for epilepsy treatment broadens its intellectual property protection outside the USA, where it already holds 6 existing patents [2] - The new patent for sublingual delivery of nicotine adds to existing patents in the USA and Canada, further solidifying Lexaria's position in the nicotine market [3] - The new patents are seen as a strategic move to enhance commercial opportunities within the pharmaceutical industry and to build long-term value for shareholders [2] Market Context - Approximately 50 million people in the US are affected by epilepsy, highlighting a substantial patient population for potential treatments [4] - The nicotine pouch market, where Lexaria's DehydraTECH™ technology has shown absorption benefits, is expected to reach US$25.4 billion in revenue by 2030 [5] - Lexaria's DehydraTECH™ technology improves the delivery of active pharmaceutical ingredients, demonstrating increased bio-absorption and effectiveness across the blood-brain barrier [6]

Core Insights - Lexaria Bioscience Corp. will participate in the BIO International Convention in Boston from June 16-19, 2025, aiming to advance discussions with potential partners and investors [1][2] Company Overview - Lexaria is a global innovator in drug delivery platforms, specifically through its patented DehydraTECH® technology, which enhances drug absorption and reduces side effects [4] - The company holds 48 granted patents and has additional patents pending worldwide, showcasing a strong intellectual property portfolio [4] Event Participation - The BIO International Convention is the largest biotechnology convention globally, featuring over 1,500 exhibitors and 20,000 attendees, providing a platform for networking and collaboration [2] - Lexaria is arranging one-on-one meetings with corporate leaders in sectors such as weight loss, diabetes, and hypertension, with limited meeting slots still available [3]